Myndtec, Inc. · CSE:MYTC
Myndtec — Investor Presentation (February 2025)
31 slides from Myndtec's investor presentation, Feb 25, 2025
Slide 1: A Neurological Treatment and Rehabilitation Medical Technology Company
A Neurological Treatment and Rehabilitation Medical Technology Company CSE : MYTC January 2025
Slide 2: Cautionary Note - Forward Looking Statements
Cautionary Note - FORWARD LOOKING STATEMENTS This presentation (the “Presentation”) of MyndTec Inc. (the “Company”) is current as of January 27, 2025, except as otherwise provided herein. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as
Slide 3: Cautionary Note - Forward Looking Statements (continued)
Cautionary Note - FORWARD LOOKING STATEMENTS (continued) No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained
Slide 4: Cautionary Note - Forward Looking Statements (continued)
Cautionary Note - FORWARD LOOKING STATEMENTS (continued) The forward-looking statements and FOFI contained in this document are expressly qualified by this cautionary statement. Certain information contained herein is based on, or derived from, information provided by independent third-party sources
Slide 5: What We Do?
What We Do? AI Enhanced Treatments Better Patient Outcomes Significant Cost Savings Use of AI to optimize treatments for chronic Improved treatment success rates lead to Efficient treatments for improved pain and movement disorders. enhanced quality of life. outcomes and reduced costs. MyndTec bring
Slide 6: Chronic Pain, (Unfortunately), is a Large and Growing Market
Chronic Pain, (Unfortunately), is a Large and Growing Market The Role of Spinal Cord Stimulator (SCS) Devices in Pain Management and Impact of AI-Enabled Options 24.3% of adults experienced chronic pain, and 8.5% of adults experienced high - impact chronic pain in 2023 in US. (Sohi, 2023) The SCS ma
Slide 7: Spinal Cord Stimulation (SCS): Transforming Lives, One Patient at a Time
Spinal Cord Stimulation (SCS): Transforming Lives, One Patient at a Time • What is SCS? o A small, implanted device that sends mild electrical pulses to the spinal cord, interrupting pain signals and providing relief for chronic pain.1 o It is like a "pacemaker for pain," using mild electrical pulse
Slide 8: One Size Doesn't Fit All
One Size Doesn’t Fit All Challenges in Spinal Cord Stimulation (SCS) Treatments Ineffectiveness: SCS is a leading treatment. ~50,000 SCS are implanted annually in U.S. (Staats et al, 2023) ~30% experience no improvement (Hadanny et al, 2022). Economic Impact: SCS costs approximately $3.5 billi
Slide 9: The MyndLink Solution
The MyndLink Solution AI is Poised to Make Huge Impact in Improving Efficacy of Treatments MyndLinkTM is MyndTec’s AI software platform being developed to integrate with any SCS device used for chronic pain. Compatibility Accuracy Cost Efficiency Any SCS Projected 88% Accuracy Projected $1B in Savin
Slide 10: AI Most Applicable Market is Healthcare
AI Most Applicable Market is Healthcare Where We Play AI is transforming healthcare Impact Projected growth: $187.95 billion by 2030, $150 billion in annual savings for the US a 37% CAGR (GlobeNewsWire, 2022). healthcare system by 2026 through AI applications (ICT&health, 2017). MyndTec is at the fo
Slide 11: MyndLink: Transforming Spinal Cord Stimulation (SCS)
MyndLink: Transforming Spinal Cord Stimulation (SCS) Feature Current SCS Approach MyndLink Solution Potential Patient Selection Doctor's experience, trial-and-error AI-powered prediction of treatment success Failure Rate 30-40% Target: < 10%. Further accuracy increase to 88%+ in Pre-ML Model Accurac
Slide 12: Go To Market Strategy
Go To Market Strategy Commercializing MyndLink Platform MyndTec is developing MyndLink to launch it through a three-pronged commercialization strategy: Hospital & Surgery Centers Device Manufacturer Partnerships Physician Pre-Screening Direct sales of MyndLink as Software as Collaborating with leadi
Slide 13: Revenue Model – Capturing Value & Driving Growth
Revenue Model – Capturing Value & Driving Growth Assumptions 1. Average Savings Per Facility* = $1,270,500 2. MyndLink @ 18% of savings =$224,874 3. No. of Facilities = 720** One time set up fee: $10,000 Covers implementation, training, and integration Base Annual Subscription: $50,000 Provides acce
Slide 14: MyndLink Anticipated Go-To-Market Paths
MyndLink Anticipated Go-To-Market Paths FDA Commercialization Plan Clinical Development FDA Pathway CommercializationMyndli nk ML Model Validation 510k-Exempt Reimbursement Plan New billable code available Clinical Decision Support upon approval. Software. FDAPathway Reimbursement planning: Apply
Slide 15: MyndLink Timeline
MyndLink Timeline 2025 2026 Q1-25 Q2-25 Q3-25 Q4-25 Q1-26 Q2-26 Q3-26 Data Preparation, & Advanced Modeling & AI Model Deployment Initial Modeling Optimization Strategy Strategic Clinical Limited Commercial Deployment Launch MyndLink Non-Device 510k-Exempt Clinical Decision Support Software DEVELOPM
Slide 16: Future Development
Future Development MyndLink is MyndTec’s foundation for today's advancements and tomorrow's cures in neurological care. We are expanding MyndLink to personalize Deep Brain Stimulation (DBS) for Parkinson's and Essential Tremor, leveraging patented brain-mapping technology. Beyond DBS, MyndTec may le
Slide 17: Intellectual Property
Intellectual Property Patent portfolio with patents and patent applications granted and pending worldwide, including: Electrical stimulation Implantable devices Multi-modal brain-mapping for personalized treatment Licensing of technologies from the University Health Network, University of
Slide 18: Current Offering: Non-Brokered Private Placement
CURRENT OFFERING NON–brokered Private Placement Issuer: MyndTec Inc. Non-brokered private placement of up to 7,500,00 units of the Company (each, a “Unit”), to Offering: raise aggregate gross proceeds to the Company of up to $1,500,000 (the “Offering”). Issue Price: C$0.20 per Unit. Each Unit shall
Slide 19: Use of Proceeds
Use of Proceeds Key Expenditures ($) CAD Dollar Amount Development of Machine Learning Model 400,000 Settle outstanding debt obligations (FEDA loan) 300,000 Investor Relations and Marketing 200,000 General and Administrative Costs 600,000 Total 1,500,000 Use of proceeds breakdown is estimated, and a
Slide 20: Capital Structure
CAPITAL STRUCTURE CAPITALIZATION INFO (Dec. 31, 2024) LEADERSHIP Stock Symbol MYTC Craig Leon Chief Executive Officer Share Price $0.20 (Jan 27, 2025) Scott Franklin Chief Financial Officer Market Capitalization CAD $5.0M Mark Shiwram Technical Support Engineer Common Shares 25 M Yesmil Pena Quality
Slide 21: Advisory Board
Advisory Board Dr. Joseph Geraci, Ph.D: Dr. Andres Lozano, OC, MD, PhD: Lead AI Advisor; Founder, Netramark (AIAI.V). World-renowned neurosurgeon; Pioneer in Deep Specializing in mathematics, medical science, and Brain Stimulation (DBS) and focused ultrasound. quantum machine learning. 830+
Slide 22: Investment Highlights
Investment Highlights First-Mover Advantage: Pioneering AI-driven neuromodulation to revolutionize treatment for chronic pain and movement disorders. Large & Growing Market: Addressing a multi-billion dollar market with a unique platform that both optimizes existing therapies and enables future
Slide 23: Contact information
CSE: MYTC Contact information MyndTec Inc. Head Office: 1900 Minnesota Court, Suite 122 Mississauga, ON, CANADA L5N 3C9 For further information visit: www.myndtec.com Craig Leon | CEO Bill Mitoulas | Investor Relations craig.leon@myndtec.com billm@venturenorthcapital.com C SE: MYTC Strictly c onfide
Slide 24: References
References Aydin SO, Tasargol O. Spinal Cord Stimulation and Related Health Information on Social Media: An Analysis of Instagram Posts. Cureus. 2023 Sep 12;15(9):e45129. doi: 10.7759/cureus.45129. PMID: 37842402; PMCID: PMC10569752. Becker’s Hospital Review. (2020). Average cost per operating r
Slide 25: References
References Journal of Neurosurgery: Spine. (2020). Cost analysis of spinal cord stimulation. Retrieved from https://www.jneurosurgery.org Kumar, K., & Bishop, S. (2009). Financial impact of SCS on healthcare budgets. Journal of Neurosurgery: Spine. DOI: 10.3171/2009.2.SPINE0865National Spinal Co
Slide 26: Appendix I - Statutory and Contractual Rights of Action
Appendix I - Statutory and Contractual Rights of Action Securities legislation in certain of the provinces of Canada and other jurisdictions outside of Canada, as applicable, provides investors with rights of rescission or damages, or both, where an offering memorandum or any amendment to it contain
Slide 27: Appendix I - Statutory and Contractual Rights of Action (continued)
Appendix I - Statutory and Contractual Rights of Action (continued) Alberta, British Columbia and Québec Investors. By purchasing securities of the Company, investors in Alberta, British Columbia and Québec are not entitled to the statutory rights described above. In consideration of their purchase
Slide 28: Appendix I - Statutory and Contractual Rights of Action (continued)
Appendix I - Statutory and Contractual Rights of Action (continued) Similar rights of action for damages and rescission are provided in Saskatchewan legislation in respect of a misrepresentation in advertising and sales literature disseminated in connection with an offering of securities. Saskatchew
Slide 29: Appendix I - Statutory and Contractual Rights of Action (continued)
Appendix I - Statutory and Contractual Rights of Action (continued) Nova Scotia Investors. Under Nova Scotia securities legislation, certain investors who purchase securities offered by an offering memorandum during the period of distribution will have a statutory right of action for damages against
Slide 30: Appendix I - Statutory and Contractual Rights of Action (continued)
Appendix I - Statutory and Contractual Rights of Action (continued) Prince Edward Island Investors If an offering memorandum, together with any amendment thereto, is delivered to a investor and the offering memorandum, or any amendment thereto, contains a misrepresentation, a investor has, without r
Slide 31: Appendix I - Statutory and Contractual Rights of Action (continued)
Appendix I - Statutory and Contractual Rights of Action (continued) Manitoba Investors. If an offering memorandum or any amendment thereto, sent or delivered to a investor contains a misrepresentation, the investor who purchases the security is deemed to have relied on the misrepresentation if it wa